NASDAQ:CRME - Cardiome Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.33 0.00 (0.00 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$2.33
Today's RangeN/A
52-Week Range$1.29 - $4.84
VolumeN/A
Average Volume135,322 shs
Market Capitalization$81.25 million
P/E Ratio-2.59
Dividend YieldN/A
Beta0.19

About Cardiome Pharma (NASDAQ:CRME)

Cardiome Pharma logoCardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Receive CRME News and Ratings via Email

Sign-up to receive the latest news and ratings for CRME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRME
CUSIPN/A
Phone604-677-6905

Debt

Debt-to-Equity Ratio4.31
Current Ratio3.97
Quick Ratio3.99

Price-To-Earnings

Trailing P/E Ratio-2.59
Forward P/E Ratio-3.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$24 million
Price / Sales3.39
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book8.96

Profitability

EPS (Most Recent Fiscal Year)($0.90)
Net Income$-29,810,000.00
Net Margins-125.98%
Return on Equity-164.75%
Return on Assets-47.61%

Miscellaneous

Employees120
Outstanding Shares34,870,000

Cardiome Pharma (NASDAQ:CRME) Frequently Asked Questions

What is Cardiome Pharma's stock symbol?

Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME."

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Co. (NASDAQ:CRME) announced its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $6.54 million for the quarter, compared to analyst estimates of $7.34 million. Cardiome Pharma had a negative return on equity of 164.75% and a negative net margin of 125.98%. View Cardiome Pharma's Earnings History.

When is Cardiome Pharma's next earnings date?

Cardiome Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Cardiome Pharma.

What price target have analysts set for CRME?

3 equities research analysts have issued twelve-month price targets for Cardiome Pharma's stock. Their predictions range from $5.00 to $10.00. On average, they anticipate Cardiome Pharma's share price to reach $7.50 in the next twelve months. View Analyst Ratings for Cardiome Pharma.

What are Wall Street analysts saying about Cardiome Pharma stock?

Here are some recent quotes from research analysts about Cardiome Pharma stock:
  • 1. According to Zacks Investment Research, "Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function. " (11/14/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 21, 2017, 09:42 ET Date and time of production: August 21, 2017, 09:42 ET Target Price / Valuation Methodology: Cardiome Pharma Corp. – CRME Discounted cash flow analysis supports an $8 valuation for CRME shares Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $8/share for CRME, assuming continued progress on the Brinavess Canada and Xydalba launches along with a potential Trevyent launch in 2019. We estimate a weighted average cost of capital (WACC) of 11.2%, which assumes an 88% equity/total capital structure at a 10.3% cost of equity capital and a 12% debt/total capital structure at a 14% cost of debt. We use a long-term estimated tax rate of 22% and a terminal growth decline of 1% in our analysis. For cash management purposes, our analysis assumes an equity raise in 2H/17 but management has not publicly commented on the possibility of future capital raises. Risks to achieving Target Price / Valuation: Cardiome Pharma Corp. – CRME OUS payers and providers can be more difficult to predict – Given the relative lack of market data compared to the US coupled with a fragmented payer landscape, variability in physician training and standard of care modalities, and different preferences in patient populations in OUS markets, the marketability of a product in these environments can be more difficult to predict than in the US." (8/21/2017)

Who are some of Cardiome Pharma's key competitors?

Who are Cardiome Pharma's key executives?

Cardiome Pharma's management team includes the folowing people:
  • Dr. William L. Hunter, Pres, CEO & Director (Age 55)
  • Ms. Sheila M. Grant MBA, Chief Operating Officer
  • Mr. David D. McMasters, Gen. Counsel (Age 59)
  • Mr. Hugues Sachot, Chief Commercial Officer
  • Mr. Justin A. Renz, Chief Financial Officer (Age 46)

Has Cardiome Pharma been receiving favorable news coverage?

News articles about CRME stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cardiome Pharma earned a media sentiment score of 0.11 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.76 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Cardiome Pharma's major shareholders?

Cardiome Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include WESTFIELD CAPITAL MANAGEMENT COMPANY LP (12.62%), WESTFIELD CAPITAL MANAGEMENT COMPANY LP (12.62%), Westfield Capital Management Co. LP (12.02%), WESTFIELD CAPITAL MANAGEMENT COMPANY LP (11.90%) and CLOUGH CAPITAL PARTNERS L P (5.90%). View Institutional Ownership Trends for Cardiome Pharma.

Which major investors are selling Cardiome Pharma stock?

CRME stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP. View Insider Buying and Selling for Cardiome Pharma.

How do I buy shares of Cardiome Pharma?

Shares of CRME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cardiome Pharma's stock price today?

One share of CRME stock can currently be purchased for approximately $2.33.

How big of a company is Cardiome Pharma?

Cardiome Pharma has a market capitalization of $81.25 million and generates $24 million in revenue each year. The biopharmaceutical company earns $-29,810,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Cardiome Pharma employs 120 workers across the globe.

How can I contact Cardiome Pharma?

Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at [email protected]


MarketBeat Community Rating for Cardiome Pharma (CRME)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe CRME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRME will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cardiome Pharma (NASDAQ:CRME) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Cardiome Pharma in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 221.89%. The high price target for CRME is $10.00 and the low price target for CRME is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50$7.50$7.25$6.4167
Price Target Upside: 221.89% upside242.47% upside386.58% upside322.15% upside

Cardiome Pharma (NASDAQ:CRME) Consensus Price Target History

Price Target History for Cardiome Pharma (NASDAQ:CRME)

Cardiome Pharma (NASDAQ:CRME) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018HC WainwrightSet Price TargetBuy$10.00MediumView Rating Details
3/21/2018Canaccord GenuitySet Price TargetBuy$5.00LowView Rating Details
12/15/2017MackieUpgradeBuyLowView Rating Details
12/22/2016Leerink SwannInitiated CoverageOutperform$4.75N/AView Rating Details
11/9/2016Bloom BurtonReiterated RatingBuyN/AView Rating Details
8/15/2016Brean CapitalReiterated RatingBuy$10.00 ➝ $7.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Cardiome Pharma (NASDAQ:CRME) Earnings History and Estimates Chart

Earnings by Quarter for Cardiome Pharma (NASDAQ:CRME)

Cardiome Pharma (NASDAQ:CRME) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-0.53 EPS

Cardiome Pharma (NASDAQ CRME) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/15/2018Q1($0.22)($0.24)$7.34 million$6.54 millionViewListenView Earnings Details
3/13/2018Q4 2017($0.19)($0.24)$7.94 million$7.00 millionViewN/AView Earnings Details
11/14/2017n/a($0.16)($0.20)$7.42 million$6.02 millionViewN/AView Earnings Details
8/8/20176/30/2017($0.18)($0.26)$6.88 million$5.75 millionViewListenView Earnings Details
5/15/20173/31/2017($0.15)($0.20)$6.96 million$5.19 millionViewN/AView Earnings Details
3/7/2017Q4($0.16)($0.18)$6.72 million$7.00 millionViewListenView Earnings Details
11/7/2016Q316($0.20)($0.19)$5.68 million$5.20 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.37)$6.73 million$5.90 millionViewN/AView Earnings Details
5/13/2016Q116($0.21)($0.06)$6.34 million$7.10 millionViewListenView Earnings Details
3/10/2016Q415($0.19)($0.37)$7.74 million$4.70 millionViewListenView Earnings Details
11/13/2015Q315($0.23)($0.31)$7.08 million$5.00 millionViewListenView Earnings Details
8/5/2015Q215($0.25)($0.43)$7.67 million$5.70 millionViewN/AView Earnings Details
5/13/2015Q115($0.28)($0.23)$7.48 million$5.50 millionViewListenView Earnings Details
3/12/2015Q414($0.14)($0.39)$8.54 million$7.00 millionViewN/AView Earnings Details
11/7/2014Q314($0.13)($0.26)$6.20 million$7.81 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.16)($0.26)$6.77 million$7.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.11)($0.20)$8.08 million$7.60 millionViewN/AView Earnings Details
3/27/2014($0.22)($0.53)$2.52 million$3.90 millionViewN/AView Earnings Details
11/6/2013Q3 13($0.21)($0.29)$0.48 millionViewN/AView Earnings Details
8/2/2013Q2 13($0.19)($0.22)$0.10 millionViewN/AView Earnings Details
5/13/2013Q113$1.48$1.47$1.60 million$0.10 millionViewN/AView Earnings Details
3/15/2013Q412($0.05)$0.13$0.84 millionViewN/AView Earnings Details
11/13/2012Q312($0.11)($0.22)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.30)($0.44)ViewN/AView Earnings Details
5/11/2012Q1 2012($0.35)($0.51)ViewN/AView Earnings Details
3/27/2012Q4 2011($0.50)($0.50)ViewN/AView Earnings Details
11/4/2011($0.10)($0.12)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.50)($0.65)ViewN/AView Earnings Details
5/16/2011($0.11)($0.12)ViewN/AView Earnings Details
3/10/2011($0.08)($0.12)ViewN/AView Earnings Details
11/11/2010Q3 2010$1.90$1.85ViewN/AView Earnings Details
8/11/2010Q2 2010$0.65$0.40ViewN/AView Earnings Details
5/11/2010Q1 2010$0.15$1.30ViewN/AView Earnings Details
3/9/2010Q4 2009$0.20$0.97ViewN/AView Earnings Details
11/9/2009Q3 2009$0.85($0.03)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.55)($0.09)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.80)($0.75)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.90)($0.58)ViewN/AView Earnings Details
8/12/2008Q2 2008($1.10)($1.39)ViewN/AView Earnings Details
5/13/2008Q1 2008($1.35)($1.75)ViewN/AView Earnings Details
3/26/2008Q4 2007($1.30)($2.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cardiome Pharma (NASDAQ:CRME) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cardiome Pharma (NASDAQ CRME) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 50.49%
Insider Trading History for Cardiome Pharma (NASDAQ:CRME)
Insider Trading History for Cardiome Pharma (NASDAQ:CRME)

Cardiome Pharma (NASDAQ CRME) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Cardiome Pharma (NASDAQ CRME) News Headlines

Source:
DateHeadline
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess® in ChinaCorrevio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess® in China
finance.yahoo.com - May 17 at 9:22 AM
Cardiome Pharma (CRME) Announces  Earnings ResultsCardiome Pharma (CRME) Announces Earnings Results
www.americanbankingnews.com - May 16 at 10:39 AM
Cardiome Pharmas (CRME) CEO William Hunter on Q1 2018 Results - Earnings Call TranscriptCardiome Pharma's (CRME) CEO William Hunter on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 9:50 AM
Cardiome: 1Q Earnings SnapshotCardiome: 1Q Earnings Snapshot
finance.yahoo.com - May 15 at 4:42 PM
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 ...Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 ...
www.prnewswire.com - May 11 at 4:52 PM
Cardiome Pharma (CRME) Set to Announce Quarterly Earnings on TuesdayCardiome Pharma (CRME) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 11 at 11:17 AM
$7.34 Million in Sales Expected for Cardiome Pharma Co. (CRME) This Quarter$7.34 Million in Sales Expected for Cardiome Pharma Co. (CRME) This Quarter
www.americanbankingnews.com - May 11 at 1:44 AM
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference CallCardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
finance.yahoo.com - May 10 at 9:28 AM
Zacks: Brokerages Expect Cardiome Pharma Co. (CRME) Will Announce Earnings of -$0.22 Per ShareZacks: Brokerages Expect Cardiome Pharma Co. (CRME) Will Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - May 9 at 11:16 PM
Cardiome Pharma Corp (TSE:COM): Should The Recent Earnings Drop Worry You?Cardiome Pharma Corp (TSE:COM): Should The Recent Earnings Drop Worry You?
finance.yahoo.com - May 8 at 9:14 AM
Cardiome Pharma (CRME) Upgraded to Sell at ValuEngineCardiome Pharma (CRME) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 8:24 PM
US STOCKS ON THE MOVE-Sprint, T-Mobile, SteadyMed, AndeavorUS STOCKS ON THE MOVE-Sprint, T-Mobile, SteadyMed, Andeavor
www.nasdaq.com - May 2 at 4:42 PM
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor ConferenceCardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 26 at 4:39 PM
Cardiome Pharma Co. (CRME) Expected to Announce Quarterly Sales of $7.34 MillionCardiome Pharma Co. (CRME) Expected to Announce Quarterly Sales of $7.34 Million
www.americanbankingnews.com - April 24 at 2:46 AM
Zacks: Brokerages Anticipate Cardiome Pharma Co. (CRME) to Post -$0.22 EPSZacks: Brokerages Anticipate Cardiome Pharma Co. (CRME) to Post -$0.22 EPS
www.americanbankingnews.com - April 22 at 3:16 PM
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®
finance.yahoo.com - April 17 at 9:22 AM
Cardiome Pharma (CRME) Upgraded by ValuEngine to "Hold"Cardiome Pharma (CRME) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 15 at 7:48 PM
Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018
finance.yahoo.com - April 12 at 10:03 AM
HC Wainwright Reiterates "$10.00" Price Target for Cardiome Pharma (CRME)HC Wainwright Reiterates "$10.00" Price Target for Cardiome Pharma (CRME)
www.americanbankingnews.com - April 11 at 11:52 PM
Cardiome Pharma (CRME) Downgraded by ValuEngineCardiome Pharma (CRME) Downgraded by ValuEngine
www.americanbankingnews.com - April 10 at 9:17 AM
Cardiome Pharma (CRME) PT Set at $10.00 by HC WainwrightCardiome Pharma (CRME) PT Set at $10.00 by HC Wainwright
www.americanbankingnews.com - April 9 at 10:52 PM
-$0.20 EPS Expected for Cardiome Pharma Co. (CRME) This Quarter-$0.20 EPS Expected for Cardiome Pharma Co. (CRME) This Quarter
www.americanbankingnews.com - April 5 at 5:24 PM
HC Wainwright Analysts Give Cardiome Pharma (CRME) a $10.00 Price TargetHC Wainwright Analysts Give Cardiome Pharma (CRME) a $10.00 Price Target
www.americanbankingnews.com - April 4 at 8:04 AM
Cardiome Pharma (CRME) Reports Progress of Partner SteadyMed Towards Trevyent NDA ResubmissionCardiome Pharma (CRME) Reports Progress of Partner SteadyMed Towards Trevyent NDA Resubmission
www.streetinsider.com - April 2 at 4:43 PM
Cardiome Highlights Partner SteadyMeds Progress Towards Trevyent NDA ResubmissionCardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission
finance.yahoo.com - April 2 at 10:01 AM
Cardiome Announces Recent Insider PurchasesCardiome Announces Recent Insider Purchases
finance.yahoo.com - March 28 at 9:10 AM
Cardiome Pharma (CRME) Given a $5.00 Price Target by Canaccord Genuity AnalystsCardiome Pharma (CRME) Given a $5.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - March 22 at 10:54 PM
Canaccord: Cardiome Pharmas Sale Of Canadian Business A Highly Positive Catalyst For SharesCanaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares
www.msn.com - March 22 at 9:20 AM
Health Canada Accepts Cardiomes Xydalba New Drug Submission and Grants Priority ReviewHealth Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
finance.yahoo.com - March 22 at 9:20 AM
Cardiome Pharma Agrees to Sell Drug Portfolio, Analysts Target Price, Financial ReviewCardiome Pharma Agrees to Sell Drug Portfolio, Analysts Target Price, Financial Review
finance.yahoo.com - March 22 at 9:20 AM
Cardiome Pharma (CRME) Given a $10.00 Price Target by HC Wainwright AnalystsCardiome Pharma (CRME) Given a $10.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 21 at 1:48 PM
Cipher to Acquire Canadian Business Portfolio of Cardiome Pharma (CRME)Cipher to Acquire Canadian Business Portfolio of Cardiome Pharma (CRME)
www.streetinsider.com - March 21 at 9:47 AM
Cardiome Pharma Corp (CRME) Expected to Announce Quarterly Sales of $7.75 MillionCardiome Pharma Corp (CRME) Expected to Announce Quarterly Sales of $7.75 Million
www.americanbankingnews.com - March 21 at 4:04 AM
Cardiome Pharma Corp (CRME) Expected to Post Earnings of -$0.20 Per ShareCardiome Pharma Corp (CRME) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - March 19 at 5:14 PM
Cardiome Reports Fourth Quarter and Full Year 2017 Financial ResultsCardiome Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 13 at 4:58 PM
Marapharm Ventures Inc. Appoints Corey Klassen as Vice President of Corporate Development, Hires CFO and Adds Additional Independent DirectorMarapharm Ventures Inc. Appoints Corey Klassen as Vice President of Corporate Development, Hires CFO and Adds Additional Independent Director
finance.yahoo.com - March 8 at 10:31 AM
Cardiome Pharma (CRME) Scheduled to Post Quarterly Earnings on TuesdayCardiome Pharma (CRME) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 7 at 1:26 PM
Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13
finance.yahoo.com - March 6 at 4:38 PM
Cardiome Pharma Corp (CRME) Position Lifted by Stonepine Capital Management LLCCardiome Pharma Corp (CRME) Position Lifted by Stonepine Capital Management LLC
www.americanbankingnews.com - March 6 at 12:06 PM
Tamarack Advisers LP Boosts Position in Cardiome Pharma Corp (CRME)Tamarack Advisers LP Boosts Position in Cardiome Pharma Corp (CRME)
www.americanbankingnews.com - March 6 at 10:30 AM
Zacks: Analysts Anticipate Cardiome Pharma Corp (CRME) Will Announce Quarterly Sales of $7.94 MillionZacks: Analysts Anticipate Cardiome Pharma Corp (CRME) Will Announce Quarterly Sales of $7.94 Million
www.americanbankingnews.com - March 4 at 4:34 AM
Are Cardiome Pharma Corp’s (TSE:COM) Interest Costs Too High?Are Cardiome Pharma Corp’s (TSE:COM) Interest Costs Too High?
finance.yahoo.com - February 26 at 4:39 PM
$7.94 Million in Sales Expected for Cardiome Pharma Corp (CRME) This Quarter$7.94 Million in Sales Expected for Cardiome Pharma Corp (CRME) This Quarter
www.americanbankingnews.com - February 15 at 3:52 AM
Zacks: Analysts Expect Cardiome Pharma Corp (CRME) Will Announce Earnings of -$0.19 Per ShareZacks: Analysts Expect Cardiome Pharma Corp (CRME) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - February 13 at 7:12 PM
CRME: Initiating CoverageCRME: Initiating Coverage
finance.yahoo.com - February 5 at 3:24 PM
Cardiome Pharma Corp (CRME) to Post FY2017 Earnings of ($0.81) Per Share, Zacks Investment Research ForecastsCardiome Pharma Corp (CRME) to Post FY2017 Earnings of ($0.81) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - February 1 at 6:42 AM
$8.24 Million in Sales Expected for Cardiome Pharma Corp (CRME) This Quarter$8.24 Million in Sales Expected for Cardiome Pharma Corp (CRME) This Quarter
www.americanbankingnews.com - January 29 at 2:56 AM
Cardiome Pharma Corp (CRME) Expected to Post Earnings of -$0.19 Per ShareCardiome Pharma Corp (CRME) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - January 27 at 9:14 PM
-$0.19 Earnings Per Share Expected for Cardiome Pharma Corp (CRME) This Quarter-$0.19 Earnings Per Share Expected for Cardiome Pharma Corp (CRME) This Quarter
www.americanbankingnews.com - January 10 at 9:12 PM
Financial Review: Cardiome Pharma (CRME) vs. Sinovac Biotech (SVA)Financial Review: Cardiome Pharma (CRME) vs. Sinovac Biotech (SVA)
www.americanbankingnews.com - January 1 at 7:16 PM

SEC Filings

Cardiome Pharma (NASDAQ:CRME) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cardiome Pharma (NASDAQ:CRME) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cardiome Pharma (NASDAQ CRME) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.